Transgene Sa · EURONEXT:TNG
Transgene Sa — World Vaccine Congress, Washington D.C. 2026
26 slides from Transgene Sa's conference presentation, Apr 1, 2026
Slide 1: TG4050, an Individualized Neoantigen Therapeutic Vaccine in Early-Stage Cancer Treatment
TG4050, an Individualized Neoantigen Therapeutic Vaccine in Early-Stage Cancer Treatment Katell Bidet Huang, Head of Translational Medicine April 1st, 2026 1 World Vaccine Congress, Washington D.C.
Slide 2: Disclaimer
Disclaimer I am an employee of Transgene. This presentation contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. There can be no guarantee that (i) the results of pre- clinical work a
Slide 3: Where Are We After 5000 Years of Treatment Strategies Against Solid Tumors?
Where Are We After 5000 Years of Treatment Strategies Against Solid Tumors? 3000 BC - 1890 1900 1940 1980 2010 Beyond 2026 Surgery Radio- Chemo- Targeted Immune • ADCs therapy therapy therapies Checkpoint • Bi-specific antibodies (TKI, HER2, EGFR…) inhibitors • Cancer vaccines • Trends in evolution
Slide 4: Individualized Cancer Vaccines Could Be Game Changers in Oncology
Individualized Cancer Vaccines Could Be Game Changers in Oncology Exhausted • The tumor microenvironment is highly MDSC T cell immunosuppressive: it can prevent T cell priming, infiltration and function • Checkpoint inhibitors aim to re-invigorate T cell function within tumors. This relies on the ex
Slide 5: one patient • one cancer • one vaccine
one patient • one cancer • one vaccine 5
Slide 6: TG4050 | An Individualized Neoantigen Vaccine Combining Unique Capabilities
TG4050 | An Individualized Neoantigen Vaccine Combining Unique Capabilities Click to edit Master title style NGS lab Neoantigen selection Vaccine design & GMP manufacturing Up to 30 MHC I and MHC II cancer-specific neoantigens vectorized into MVA 6
Slide 7: TG4050 | Proposed Mode of Action
TG4050 | Proposed Mode of Action Click to edit Master title style Proposed mode of action: treatment induces neoantigen-specific CD8 T cell responses which eliminate residual tumor cells and micrometastases and prevent recurrence 7
Slide 8: Clinical Evaluation of TG4050 Monotherapy in Head and Neck Cancer (HNSCC)
Clinical Evaluation of TG4050 Monotherapy in Head and Neck Cancer (HNSCC) 8
Slide 9: Selected Study Population
Selected Study Population • 7th most common cancer worldwide HNSCC • 60% diagnosed with locally advanced disease • Risk factors: HPV, smoking, alcohol • Unfavorable prognosis HPV- HNSCC • High prevalence of immune desert tumors • Limited efficacy of checkpoint inhibitors Resectable • Standard of car
Slide 10: TG4050 | HNSCC – Proof of Principle in Monotherapy
TG4050 | HNSCC – Proof of Principle in Monotherapy Randomized PHASE Click to edit Master title style1/2 | NCT04183166 | Fully enrolled Locoregionally advanced resectable HPV- HNSCC with complete response to primary treatment* * surgery and adjuvant radiotherapy +/- chemotherapy Primary endpoint Seco
Slide 11: TG4050 | HNSCC Phase 1 – Randomization and Feasibility
TG4050 | HNSCC Phase 1 – Randomization and Feasibility • 33 patients randomized, 19 received TG4050 • 16/19 vaccines contained the maximum number of 30 neoantigens. The remaining 3 contained 26, 27 and 17 neoantigens • Not a single neoantigen was shared among vaccines Feasibility and pertinence of t
Slide 12: TG4050 | HNSCC Phase 1 - Patient characteristics
TG4050 | HNSCC Phase 1 - Patient characteristics Click to edit Master title style • Most patients have primary tumors of the oral cavity • Majority of pathological stage IV • Present ≥ 1 risk factors among extracapsular extension, positive resection margin, perineural infiltration, invaded lymph nod
Slide 13: TG4050 | HNSCC Phase 1 - Safety
TG4050 | HNSCC Phase 1 - Safety Click to edit Master title style Adjuvant TG4050 (N=17) TG4050 at recurrence (N=3) Patients with at least one AE related to TG4050, n (%) 16 (94%) 2 (67%) Dose-limiting toxicity 0 0 SAE 0 0 Grade 3-5 AEs 0 0 Grade 1/2 AEs related to TG4050 Injection site reaction 16 (
Slide 14: TG4050 | HNSCC Phase 1 – 100% DFS 2 Years After Treatment Initiation
TG4050 | HNSCC Phase 1 – 100% DFS 2 Years After Treatment Initiation 2-year disease-free survival (DFS) Median follow-up of 30 months 100% • All 16 treated patients 81% remain disease-free • 3 patients in observation arm TG4050 monotherapy Observation arm relapsed Clinical proof-of-principle in adju
Slide 15: Comprehensive Characterization of the Patient's T Cell Response to Vaccine Neoantigens
Comprehensive Characterization of the Patient’s T Cell Response to Vaccine Neoantigens 15
Slide 16: TG4050 | HNSCC Phase 1 – Deciphering T Cell Responses to Neoantigens
TG4050 | HNSCC Phase 1 – Deciphering T Cell Responses to Neoantigens Click to edit Master title style 1 Quantification of the T cell response to individual neoantigens 2 Durability of the T cell response 1 2 Phenotype and 3 transcriptomic 4 3 signatures of vaccine- induced T cells Expansion and 4 di
Slide 17: TG4050 Primed and Amplified Circulating T Cell Responses to Multiple Vaccine-Encoded Neoantigens
1 TG4050 Primed and Amplified Circulating T Cell Responses to Multiple Vaccine-Encoded Neoantigens Ex vivo IFN-γ ELISpot (Baseline vs D64) pMHC-I tetramer Background-subtracted SFC/106 PBMC Patient 13 NeoA B*18:01 Gated on CD8 T cells Patient 8 NeoA B*35:01 Gated on CD8 T cells Patients • Neoantigen
Slide 18: Neoantigen-Specific CD8 T Cell Responses Persist Up to 12 Months After the End of Treatment
2 Neoantigen-Specific CD8 T Cell Responses Persist Up to 12 Months After the End of Treatment pMHC-I tetramer longitudinal analysis • Neoantigen-specific CD8 T n = number of pMHC tetramers cell responses to multiple Patient 4 (n = 1) vaccine epitopes Patient 2 (n = 1) Patient 6 (n = 2) • Responses p
Slide 19: Neoantigen-Specific CD8 T Cell Responses Are Effector Memory T Cells
3 Neoantigen-Specific CD8 T Cell Responses Are Effector Memory T Cells Phenotyping of pMHC-I tetramer+ cells Performed for all patients in longitudinal tetramer analysis Complete time-series was not available for all patients. All available time-points are shown • Neoantigen specific T cells have a
Slide 20: scRNAseq Analysis Shows Neoantigen-Specific CD8 T Cells Harbor Signatures of Cytotoxicity
3 scRNAseq Analysis Shows That Neoantigen-Specific CD8 T Cells Harbor Signatures of Cytotoxicity, Tissue Residency and Antigen Experience scRNAseq Neoepitope (CCR7, MVA Memory TCF7, Flu IL7R) CMV Cytotoxic (ZNF683, tissue- GNLY, SELL, GZMB, resident PRF1) DEG of markers Activated (GZMK, associated w
Slide 21: TG4050 Induces Expansion and Diversification of the T Cell Repertoire
4 TG4050 Induces Expansion and Diversification of the T Cell Repertoire Clonality of tetramer+ CD8 T cells Expansion of tumor-associated clones Clonality index n clonotypes n cells Clone frequency in blood Patient 10 Patient 2 Flu 0.32 Patient 2 CMV 0.62 MVA 0.01 Neo2A - Patient 4 Neo4A Patient 4 0.
Slide 22: Key Takeaway Points
Key Takeaway Points Click to edit Master title style 1 2 3 4 Adjuvant TG4050 DFS data from TG4050 induces Neoantigen-specific individualized randomized Phase 1 long-lasting T cells harbor vaccination is in monotherapy de novo and recalls cytotoxicity and feasible and safe in support TG4050’s CD8 T c
Slide 23: TG4050 and Individualized Cancer Vaccines What is Next?
TG4050 and Individualized Cancer Vaccines What is Next? 23
Slide 24: TG4050 and Individualized Vaccination | What's Next?
TG4050 and Individualized Vaccination | What’s Next? Click to edit Master title style 3 INTV Multiple positive data from players TG4050 Phase 2 – HNSCC 1 in the field: strong proof of • Randomization close to being completed principle that INTV could be game • Readouts expected in 2026 changers in o
Slide 25: Acknowledgments
Acknowledgments The authors wish to thank all patients, families, caregivers and all technical staff involved in the trial Thank you for your attention April 1st, 2026 World Vaccine Congress, Washington, D.C. 25
Slide 26: Katell Bidet Huang
CONTACT Katell Bidet Huang Head of Translational Medicine, Transgene bidet_huang@transgene.fr 400 Boulevard Gonthier d’Andernach | Parc d’Innovation | CS80166 67405 Illkirch Graffenstaden Cedex | France Tél.: + 33 (0)3 88 27 91 00 | www.transgene.com 26
Transgene — World Vaccine Congress, Washington D.C. 2026 on 6ix